
Evolent Health (EVH) Stock Forecast & Price Target
Evolent Health (EVH) Analyst Ratings
Bulls say
Evolent Health Inc. has demonstrated a strong growth trajectory, with an expected substantial increase in its legacy Performance Suite Medical Expense Ratio (MER) and an anticipated sequential EBITDA improvement of $10-15 million in the upcoming quarters. The company's ability to cross-sell services and expand its risk-based product offerings to large clients positions it well for outsized growth, particularly with a target of $150 million in EBITDA by the end of 2026. Furthermore, Evolent Health is on track for significant top-line growth and improved margins, which underscores its leadership in specialty-focused, value-based care services.
Bears say
Evolent Health Inc.'s outlook appears negative due to projected revenue declines, specifically with a forecasted loss of approximately $100 million stemming from the legacy Performance Suite, leading to an anticipated revenue of about $850 million for that segment in 2026. Additionally, the company's guidance indicates only $20 million in EBITDA for the first quarter, with expectations for flat sequential performance in Q2, suggesting limited growth potential in the near term. Furthermore, downward adjustments to earnings per share estimates for fiscal years 2026 and 2027, along with a significant reduction in the price target, reflect a lack of confidence in the company's ability to stabilize its financial performance amidst ongoing market challenges.
This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.
Evolent Health (EVH) Analyst Forecast & Price Prediction
Start investing in Evolent Health (EVH)
Order type
Buy in
Order amount
Est. shares
0 shares